Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Vizuro and DCB Join Forces to Revolutionize Drug Discovery and Precision Medicine with Causal Generative AI


News provided by

Vizuro LLC

Dec 26, 2024, 08:30 ET

Share this article

Share toX

Share this article

Share toX

Vizuro LLC, a leading innovator in multimodal causal AI technology, and the Development Center for Biotechnology (DCB) announced the signing of a Memorandum of Understanding (MOU)

BOSTON, Dec. 26, 2024 /PRNewswire-PRWeb/ -- Vizuro LLC, a leading innovator in multimodal causal AI technology, and the Development Center for Biotechnology (DCB) announced the signing of a Memorandum of Understanding (MOU) to collaboratively drive innovation and growth in the biotechnology and pharmaceutical industries.

This collaboration aims to establish a next-generation AI computational platform, advancing breakthroughs in drug discovery and accelerating the implementation of precision medicine. The partnership paves the way for groundbreaking advancements in the global biotech industry.

Vizuro LLC is a pioneering provider of multimodal causal AI technology with offices in Boston, USA, and Taipei, Taiwan. The company delivers actionable AI solutions across multiple industries, serving a global clientele over the past decade. Vizuro's partnerships span organizations of all sizes, from Fortune 100 companies to emerging startups. In 2024, Vizuro was twice recognized as an exemplary vendor by Gartner in its Hype Cycle reports for AI technologies and advanced analytics in financial services.

DCB is a key player in Taiwan's biotech value chain, and is recognized as "the best partner in the biotech industry". Supported by the Department of Industrial Technology, Ministry of Economic Affairs R.O.C, DCB has been focusing on cancer drug development, precision medicine, and innovative therapies. To align with the global surge in AI advancements, DCB has established the IntelliBio division to pioneer AI-driven innovations in drug discovery.

The MOU outlines collaboration in nine major areas, including:

  • Small-molecule drugs
  • Antibody-drug conjugates (ADC)
  • Bispecific antibodies
  • Antisense oligonucleotides (ASO)
  • Small interfering RNA (siRNA)
  • Antibody-oligonucleotide conjugates (AOC)
  • Induced pluripotent stem cells (iPSC)
  • CAR-NK cell therapy
  • Cancer vaccines

The partnership will also collaborate on securing resources from the Ministry of Economic Affairs, R.O.C., and NVIDIA's "Taipei-1" A+ program to boost the platform's AI computational capabilities. This enhanced capacity will support multimodal drug discovery and accelerate the clinical application of innovative therapies. By combining their unique expertise, Vizuro and DCB aim to create next-generation biotech products and platforms, driving progress in both research and commercial ventures.

"The causal generative AI platform developed by Vizuro enables significant advancements in drug discovery. It expands potential biological pathways, enhances target discovery, repositions drugs, and generates novel drug designs while identifying biomarkers suited for specific clinical populations. By combining DCB's extensive expertise in drug development and startup incubation with Vizuro's capabilities in causal and generative AI technology, this collaboration represents a powerful synergy. The integration of generative AI technology makes drug discovery processes more precise and efficient. This partnership with DCB opens new opportunities in drug discovery, injecting fresh momentum into the growth of Taiwan's biotech and pharmaceutical industries." Yu-Feng Wei, Co-Founder and CEO of Vizuro LLC, stated.

"Generative AI technology significantly enhances the efficiency of target exploration and drug design. By collaborating with Vizuro, a leader in generative AI, DCB aims to accelerate cancer drug development. This partnership is expected to yield niche, first-in-class, or best-in-class drugs while fostering an ecosystem for academic, industrial, and research collaborations in early-stage drug discovery. The ultimate goal is to deliver innovative medicines that benefit patients worldwide " Dr. Hsing-Jer Tsou, DCB Chairman, emphasized.

"DCB's robust preclinical drug development capabilities, with extensive experience in small-molecule drugs, biologics, and nucleic acid therapeutics. Vizuro, with offices in Boston and Taipei, specializes in generative AI and offers actionable AI solutions across various industries. Its expertise lies in combining deep learning and causal inference to identify biological targets and simulate drug designs from multimodal data. Together, DCB and Vizuro plan to build an AI computational platform to advance drug discovery and repositioning, efficiently finding new therapeutic uses for existing drugs. This will accelerate the development of cost-effective, precise, and rapid new medicines." Dr. Chien-Yueh Huang, DCB Deputy Executive Director, highlighted.

This collaboration marks a major leap forward in generative AI in the biotechnology and pharmaceutical sectors. It establishes a new standard for integrating AI technologies and propelling Taiwan's biotech industry into the global market.

Media Contact

Finnie Lu, Vizuro LLC, 886 903363701, [email protected], https://www.vizuro.com/

SOURCE Vizuro LLC

Modal title

Vizuro and DCB join forces to revolutionize drug discovery and precision medicine with Causal Generative AI
Vizuro and DCB join forces to revolutionize drug discovery and precision medicine with Causal Generative AI
Vizuro and DCB join forces to revolutionize drug discovery and precision medicine with Causal Generative AI

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.